|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase Ⅲ study 显示文摘 | Fenaux P Mufti GJ Hellstrom-Lindberg E | 2009 | Lancet Oncol2009，10，3： | 1 |
| 2 | Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study 显示文摘 | Fenaux P Mufti G J Hellstrom-Lindberg E | 2009 | Lancet Oncol2009，10，3： | 1 |
| 3 | Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes 显示文摘 | Silverman LR Fenaux P Mufti GJ | 2011 | Cancer2011，117，12： | 1 |
| 4 | Azaeitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloidleukemia显示文摘 | Fenaux P Mufti GJ Hellstrom-Lindberg E | 2010 | J Clin Oncol2010，28，4： | 1 |
| 5 | A muhieenter phase 2 study of the farnesyhransferase inhibitor tipifarnib in intermediate-to high-risk myelodys-plastic syndrome 显示文摘 | Fenaux P Raza A Mufti GJ | 2007 | Blood2007，109，： | 1 |
| 6 | Punching shear strength of restraint concrete bridge deck slabs显示文摘 | Mufti A A Newhook J P | 1998 | ACl Structural Journal1998，，78： | 1 |
| 7 | Azacitidine treatment prolongs overall survival in higher risk MDS patients compared with conventional care regimens:results of the AZA-001 phase III study显示文摘 | Fenaux P Mufti G Santini V | 2007 | Blood2007，110，： | 1 |
| 8 | Azacitidine treatment prolongs overall survival in higher risk MDS paticats compared with conventional care regimens: results of the AZA-001 phase III study 显示文摘 | Fenaux P Mufti G Santini V | 2007 | Blood2007，110，： | 1 |
| 9 | A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate to high-risk myelodysplastic syndrome 显示文摘 | Fenaux P Raza A Mufti GJ | 2007 | Blood2007，109，10： | 1 |
| 10 | Efficacy of azacitidine compared with that of conventional care regi- mens in the treatment of higher - risk myelodysplastic syn- dromes : a randomised, open - label, phase III study 显示文摘 | Fenaux P Mufti GJ Hellstrom - Lindberg E | 2009 | Lancet Onco12009，10，3： | 1 |
| 11 | Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes:a randomised,open-label,phase III study显示文摘 | Fenaux P Mufti GJ Hellstrom-Lindberg E | | 0，，03： | 1 |
| 12 | Efficacy of azacitidine compared with that of con- ventional care regimens in the treatment of higher-risk my- elodysplastic syndromes: a randomised, open- label,phase III study显示文摘 | FENAUX P MUFTI G J HELLSTROM-LINDBERG E | 2009 | Lancet Oncol2009，10，： | 1 |
| 13 | Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia显示文摘 | Fenaux P Mufti GJ Hellstr?m-Lindberg E | | 0，，04： | 1 |
| 14 | Azacitidine prolongs overall survival com- pared with conventional care regimens in elderly pa- tients with low bone marrow blast count acute mye- loid leukemia显示文摘 | FENAUX P MUFTI G J HELLSTROM-LINDBE- RG E | 2010 | J Clin Oncol2010，28，： | 1 |
| 15 | Efficacy of Azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A ran- domised, open-label, phase ]II study显示文摘 | Fenaux P Mufti GJ Hellstrom-Lindterd E | 2009 | Lancet Oncol2009，10，3： | 1 |
| 16 | Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia显示文摘 | FENAUX P MUFTI G J HELLSTROM LINDBERG E | 2010 | J Clin Oncol2010，28，： | 1 |
| 17 | Management andsupportive care measures for adverse events in patients withmyelodysplastic syndromes treated with azacitidine 显示文摘 | Santini V Fenaux P Mufti GJ | 2010 | Eur JHaematol2010，85，2： | 1 |
| 18 | Results of arandomized, double-blind study of romiplostim versus placebo inpatients with low/intermediate-1 -risk myelodysplastic syndromeand thrombocytopenia显示文摘 | Giagounidis A Mufti GJ Fenaux P | 2014 | Cancer2014，120，12： | 1 |
| 19 | Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia显示文摘 | Fenaux P Mufti GJ Hellstrom-Lindberg E | 2010 | J Clin Oncol2010，28，4： | 1 |
| 20 | Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study显示文摘 | Fenaux P Mufti Gl Hellstrom-Lindberg E | 2009 | Lancet Oncol2009，10，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员